Human pluripotent stem cells represent a unique source for cell-based therapies and regenerative medicine. The intrinsic features of these cells such as their easy accessibility and their capacity to be expanded indefinitely overcome some limitations of conventional adult stem cells. Furthermore, the possibility to derive patient-specific induced pluripotent stem (iPS) cells in combination with the current development of gene modification methods could be used for autologous cell therapies of some genetic diseases. In particular, muscular dystrophies are considered to be a good candidate due to the lack of efficacious therapeutic treatments for patients to date, and in view of the encouraging results arising from recent preclinical studies. Some hurdles, including possible genetic instability and their efficient differentiation into muscle progenitors through vector-/transgene-free methods have still to be overcome or need further optimization. Additionally, engraftment and functional contribution to muscle regeneration in pre-clinical models needs to be carefully assessed before clinical translation.
Introduction
Skeletal muscle is a dynamic tissue capable of responding to exercise, injury or disease with a remarkable regenerative response. The ability of this tissue in providing a complete regeneration is primarily due to a pool of resident stem cells named satellite cells [1] . In addition to these cells, other stem/progenitor cells have been shown to participate in muscle regeneration. Subsequently, there has been much interest in the use of adult stem cells capable of myogenesis as a cellular therapy for degenerative muscle disorders (reviewed in [2] and in this issue by Sampaolesi et al.) . However, the regenerative potential of these adult stem cells is not unlimited and exhaustion/dysfunction of muscle stem/progenitor cells has been reported in several muscular dystrophies and/or after expansion in vitro [3] [4] [5] [6] [7] [8] [9] . Recent studies have suggested the possibility of using embryonic stem (ES) cells [10, 11] or induced pluripotent stem (iPS) cells [12, 13] as a source for generating myogenic cells to use in cellular therapies for muscle regeneration. ES cells and iPS cells can be expanded indefinitely, overcoming the limitations of conventional adult muscle stem/progenitor cells. This is of particular importance for cellbased therapies of skeletal muscle disorders, since muscle is the most abundant tissue of the human body, which means that large numbers of cells would be required [14] . However, for this potential to be fulfilled, safe and efficient differentiation protocols need to be established to derive transplantable skeletal muscle progenitors from these pluripotent cells. In addition, the need to produce myogenic cells capable of regenerating skeletal muscles of the whole body of patients affected by muscular dystrophy upon systemic delivery, needs to be taken into consideration. Local intramuscular cell delivery is not a viable option to treat systemic muscle disorders since it would require a prohibitively large number of injections. In this article, we review current literature and discuss the recent challenges and future perspectives of gene and cell therapy strategies for muscular dystrophy based upon pluripotent stem cells, focusing specifically on the potential of genetically corrected myogenic cells derived from patient-specific iPS cells for autologous transplantation. To put this into context, we will also summarize the most salient features of normal skeletal muscle development and muscle regeneration.
Skeletal muscle development
Skeletal muscle embryogenesis and regenerative myogenesis share a combination of regulatory pathways and transcription factors that coax myogenic differentiation [15] . An overview of muscle development during embryogenesis helps identify the key elements that regulate the myogenic program, and that serve as a basis for the development of protocols aimed at deriving myogenic stem/progenitor cells from pluripotent stem cells.
In vertebrates, the skeletal muscles of the trunk and limbs originate from somites, spheres of paraxial mesoderm distributed in pairs on either side of the neural tube [16] [17] [18] [19] . Cells in the somites acquire lineage specification from signalling molecules emanating from their surrounding microenvironmental niche [20] [21] [22] . As somites mature they generate the dermomyotome, which contains multipotent cells that give rise to the skeletal muscles of the trunk and limbs. Interestingly, the head muscles are derived from a distinct site of origin during embryogenesis, involving distinct regulatory genes [23, 24] . In the context of hereditary myopathies, these findings might be relevant to better understand the distribution of the affected muscles compared to those that escape the disease [25, 15] . A fraction of cells of the dermomyotome will mature into the myotome, a primitive muscle structure containing progenitors expressing the regulatory factors myogenic differentiation 1 (MyoD) and myogenic factor 5 (Myf5). The remaining fraction consists of committed but undifferentiated muscle progenitors expressing the transcription factors paired box 3 (Pax3 + ) and paired box 7 (Pax7 + ). These cells will continue to proliferate without expressing differentiation markers [26] [27] [28] [29] and will give rise to embryonic, fetal myoblasts and satellite cells residing in postnatal skeletal muscle [30, 31] .
The balance between cell renewal and proliferation vs. myogenic commitment and differentiation in vertebrate development is regulated by a hierarchical cascade of gene expression, as revealed by cell lineage and gene disruption studies [32] . Pax3 and Pax7 are paired-homeobox transcription factors that dominate myogenesis. Although Pax3 plays its role primarily during embryonic development and Pax7 during the later stages, the double mutant results in the loss of body muscles from mid-embryonic stages (E12.5) [29, 28, 33] . The next level in the genetic hierarchy controlling myogenesis is dominated by the myogenic regulatory factors MyoD, Myf5, and Myf6
(myogenic factor 6). These factors are all important for the specification of the skeletal muscle lineage, as triple-mutant embryos completely lack myoblasts and skeletal muscle fibres [34] . Studies further support a regulatory network where Pax3 is genetically upstream of the MyoD family members [35, 36] . Collectively, these transcriptional regulators govern skeletal myogenesis and indeed some of them have been successfully used in recent studies to derive myogenic progenitor cells from pluripotent stem cells (e.g. Pax3/7 and MyoD).
Adult stem cells in muscle regeneration
Muscular dystrophies are degenerative skeletal muscle diseases characterized by repeated rounds of contraction-induced fibre damage [37] . These degraded fibres are replenished mainly by satellite cells; however, this has been shown to eventually lead to exhaustion of the resident stem cell populations [8] .
Due to their malfunction in muscular dystrophies, and regenerative potential, therapeutic strategies aimed at replenishing muscle-derived adult stem cells represent a promising therapeutic avenue.
Adult skeletal muscle regenerates after exercise, injury or disease. Satellite cells are thought to be the primary drivers of this regenerative capacity. Ablation of Pax7-positive satellite cells has been shown to lead to the progressive loss of the satellite cell lineage in skeletal muscle and to impede the repair of injured muscle [38] [39] [40] [41] . However, a recent study also demonstrated efficient regeneration of skeletal muscle after more than 90% reduction of satellite cells following inactivation of Pax7 [42] .
Satellite cells are mitotically quiescent in mature muscle [43] and are found in a distinct anatomical niche within the muscle, located next to the muscle fibre plasma membrane and underneath the basal lamina [1] . They express a range of characteristic, but not unique markers (reviewed in [44] ). Amongst these markers is Pax7, which has been shown to be essential for satellite cell survival [45, 46] , and Pax3
and CXCR4 (C-X-C chemokine receptor type 4), which are expressed in a subset of quiescent cells [33, 47] . Pax7 and Pax3 transcription factors have both been shown to activate the myogenic regulatory factors MyoD and Myf5 [48] [49] [50] . As highlighted in the previous section, Pax3 is essential for embryonic development of muscle [51] but is down regulated post-natally in most muscle progenitors [52] . Conversely, Pax7 is not required for embryonic myogenesis but is essential for the formation of functional adult satellite cells [45] ; although a study indicated that Pax7 was entirely dispensable in adult life [53] , more recent evidence shows that Pax7 is critical for satellite cell function in adult skeletal muscle [54] . Upon muscle injury quiescent satellite cells are activated, consistent with the expression of Myf5 and MyoD [55] . Once satellite cells have been activated they undergo asymmetric division to expand a pool of committed progenitors (i.e. the myoblasts) while preserving the compartment of undifferentiated stem cells [56] [57] [58] [59] [60] [61] . In terms of molecular markers, both quiescent and activated satellite cells can express Pax7, Myf5, Syndecan-3 and -4, VCAM-1 (vascular cell adhesion molecule 1), c-Met, Foxk1 (forkhead box protein k1), CD34, M-cadherin, caveolin-1, α 7 and l 1 integrin, CD56 and nestin. It is worth noting that some of these markers identified in mouse models do not fully correspond to those in human (i.e. CD34 is a marker of satellite cells in mice, but not in human muscle). Similarly, M-cadherin is not as consistent a marker of satellite cells in humans as it is in mice [62] . One of the more reliable markers of satellite cells/myoblasts in human muscle is CD56 [63] .
Due to the central role of satellite cells in muscle regeneration, their use for cellular therapy has been thoroughly investigated. This has been outlined in detail in this issue by Sampaolesi and coworkers, and only their most salient features will be highlighted here. Despite promising results in the mdx dystrophic mouse, clinical trials based on intra-muscular injection of allogeneic satellite cellderived myoblasts demonstrated safety but lack of efficacy [44, 64] . This could possibly be ascribed to immune rejection, poor engraftment, low survival, inefficient migration and/or differentiation.
However, these studies pioneered muscle stem cell transplantation in humans and the evidence of dystrophin production, though restricted to the injection site, is an important milestone [65] . Despite this setback, myoblast transplantation may be feasible for disorders that only affect a few isolated muscles. Indeed after promising preclinical work, a clinical trial using autologous transplantation of myoblasts isolated from non-affected muscles has shown promising results for oculopharingeal muscular dystrophy [66, 67] . This opens new perspectives for localized myoblast delivery for at least some specific types of muscular dystrophy that manifest themselves predominantly in specific anatomical locations.
To overcome the limitations of satellite cells for cell therapy, other myogenic adult stem/progenitor cells have been investigated (reviewed in [2] ). Briefly, CD133 + cells have been shown to contribute to muscle regeneration in the severe combined immunodeficient (SCID)/X chromosomelinked muscular dystrophy (mdx) mouse model for Duchenne muscular dystrophy (DMD), and preclinical and preliminary clinical studies have been conducted for the treatment of DMD [68, 69] .
Recently, these cells were shown to contribute to satellite cell formation upon intramuscular injection into immunodeficient mice [70] . PW1 + expressing interstitial cells have been identified in the mouse as a subset of cells capable of contributing to new muscle fibre formation and the satellite cell pool, although lineage tracing experiments have shown that these cells do not share the same origin as satellite cells [71] . Muscle-derived stem cells (MDSC) have been shown to lead to an improved therapeutic outcome when administered systemically to dystrophic dogs [72] .
A subpopulation of skeletal muscle pericytes normally associated with capillaries has been shown to have myogenic potential. They are typically adjacent to endothelial cells and have been identified as the human adult tissue counterpart of mesoangioblasts [73, 74] . They are a heterogeneous population and differ depending on their tissue of origin [75] . Lineage tracing experiments in mice have shown that pericytes also contribute to postnatal muscle development [73] . Importantly, pericytes/mesoangioblasts have been shown to contribute to muscle regeneration upon intra-arterial transplantation into different animal models of muscular dystrophy [76] [77] [78] [79] [80] [81] . 
Differentiation of ES cells into muscle
ES cells are pluripotent stem cells isolated from early embryos. They were first isolated from the inner cell mass of blastocyst stage mouse embryos, and their human counterpart was subsequently isolated in the 1990s [10, 11, 82] . These ground-breaking studies led to much interest in the use of these cells as a potential therapy. In the case of muscle disorders, this required the establishment of protocols for the derivation of myogenic cells, which have mostly relied on exposing the ES cells to the same factors that lead to myogenic commitment in the developing embryo (see above). The desired differentiated myogenic cells could subsequently be enriched based on the expression of specific cell surface markers. The main methods investigated for deriving myogenic cells from ES cells are summarised in [85, 86] . This could be due at least in part to inefficient myogenic differentiation that resulted in the injection of a heterogeneous population of cells, incomplete expression of MyoD in transplanted cells or high cell death upon transplantation.
Hence, there was a need to increase the robustness of myogenic differentiation of ES cell-derived myogenic cells. During normal embryogenesis and muscle regeneration, expression of the regulatory factor MyoD is associated with the induction of myogenic differentiation program [26, 55] . Initial work showed that expression of MyoD was sufficient to induce myogenic differentiation in fibroblasts [87] .
Consequently, this work justified using MyoD to also coax the myogenic differentiation of ES cells.
Transfection of murine ES cells with MyoD cDNA led to the formation of skeletal muscle-like cells capable of forming contracting myotubes in vitro after EB differentiation [88, 89] . However not all cells were converted to skeletal muscle upon MyoD expression, and the in vivo potential of these cells to engraft in skeletal muscle was not assessed.
Building upon these pioneering studies, Ozasa and colleagues engineered mouse ES cells by including an inducible, tetracycline-regulated MyoD switch [90] . Consequently, simply culturing the hypothesised that by sorting for these markers they would isolate a population of myogenic precursor cells. These ES-derived myogenic cells exhibited relatively robust engraftment, differentiation and significant improvement in muscle force generation [91] [92] [93] . This method demonstrated improved contractile properties when mouse cells were injected systemically into dystrophic mdx mice [91, 92] and was also adapted using other myogenic regulators downstream of Pax3/7 such as Myf5 [94] .
In a similar study, Sakurai and colleagues generated ES-derived muscle-like cells after FACS enrichment of PDGF-R + cells but this time without relying on genetic modification with myogenic regulatory genes [95] . However whether these cells are capable of leading to a functional improvement similar to the results seen with the Pax3/Pax7 induced cells, or if they are capable of muscle engraftment following systemic delivery, needs to be further investigated. Alternatively, satellite-like myogenic cells could be derived from ES cells using an EB-based protocol followed by FACS enrichment of SM/C-2.6 + cells [96] . SM/C-2.6 is an antibody that detects murine quiescent satellite cells, however the exact antigen that this antibody is recognising is unknown [97] . Intramuscular injection into cardiotoxin-injured mice contributed to repair of muscle damage after primary and secondary injury, and after serial transplantation. However, whether this muscle repair is sufficient to lead to functional improvement remains to be assessed. Additionally, although these results are promising, it is worth noting that the SM/C-2.6 antibody protocol is not directly applicable to human ES/iPS cells, as this antibody has only been shown to be specific for murine satellite cells. Finally, the conditioning regimen based upon cardiotoxin is clinically not relevant and only serves as a model to facilitate engraftment of the myogenic progenitors.
Recent promising work has developed further transgene free methods to drive myogenic differentiation, this time using small molecules to act on key signalling pathways. Shelton and colleagues used treatment with a WNT agonist, glycogen synthase kinase 3 (GSK-3) inhibitor, to obtain paraxial mesoderm and Pax3 + premyogenic mesoderm in human and mouse ES cells [98] .
Subsequent treatment with basic fibroblast growth factor (bFGF) was used to expand myogenic progenitor cells, followed by N2 treatment to induce terminal differentiation. This protocol used transgene-free, serum-free and chemically-defined methods; however, it requires relatively long in vitro culture times (40-50 days) to obtain myocytes and myotubes. Additionally, the in vivo potential of these cells to engraft in muscle remains to be assessed. Although commitment to the myogenic lineage was efficient, it did not occur in the entire population of cells, so further cell sorting steps maybe required before in vivo transplantation.
Recently Though these studies indicate the potential of ES cells to obtain myogenic precursor/stem cells that could be used for muscle regeneration in vivo, there are still some limitations that preclude their potential clinical use. In particular, there are ethical concerns over the use of ES cells as they are derived from, and result in the destruction of, human embryos. Nevertheless, there is an ethical framework that potentially allows for the use embryos resulting from in vitro fertilization programs that will not be re-implanted. Furthermore, recent work has shown that it maybe possible to derive human ES lines from a single cell biopsy of an eight cell in vitro fertilised embryo without its subsequent loss [102] . However, despite this promising work certain intrinsic ethical concerns over the cloning of cells from human embryos will still remain for many individuals [103] . Additionally, as these cells are indeed derived from human embryos they cannot by definition be patient-specific, and therefore autologous transplantation is not possible raising immune concerns (as detailed in the section iPS versus ES derived myogenic stem cells). Moreover, there are important safety concerns regarding the persistence of residual undifferentiated ES cells that could eventually give rise to teratomas and/or the intrinsic genetic instability of ES cells, that may perturb cellular proliferation, survival and/or differentiation. In general, there is still a need to increase the robustness of system-wide phenotypic correction in the afflicted muscle groups in dystrophic animal models by intra-vascular administration of ES-derived myogenic progenitors. This is compounded by the clearance of the ES-derived myogenic progenitors by the reticulo-endothelial system. Ultimately, it would be reassuring to have safety and efficacy data in large animal models but this is far more challenging than the initial proof of concept studies in mdx mouse models described above. Despite these caveats, these pioneering studies in ES cell research have laid the groundwork for the use of iPS cells in regenerative medicine application for degenerative muscle disorders.
Differentiation of iPS cells into muscle
The discovery of protocols to reprogram adult cells into a pluripotent embryonic-like state revolutionized stem cell biology and regenerative medicine [104] . Reprogramming was achieved by the integration of four reprogramming factors: octamer-binding transcription factor 4 (Oct4), kruppel-like factor 4 (Klf4), sex determining region Y-box 2 (Sox2) and c-Myc. These reprogramming genes need to be transiently expressed during a critical window, after which their transcription is repressed by epigenetic mechanisms. The maintenance of the pluripotency of these cells in vitro is carefully controlled by exposure to specific culture parameters, with the recent formulation of xenofree, chemically defined media and substrate [105] , which will facilitate the clinical translation of these cells and the establishment of GMP/GLP protocols. Pluripotency is lost when the cells are exposed to different culture conditions and signalling molecules, and when injected into immunocompromised mice undifferentiated iPS cells undergo spontaneous uncontrolled differentiation giving rise to teratomas [106] . Recently these results have also shown to be true for autologous iPS cells in non human primate models, however iPS cell derivatives did not demonstrate any tumour formation [107] .
To ensure that ES/iPS cell-derived myogenic progenitor/stem cells function normally in vivo after transplantation into the host, they would need to optimally integrate with the skeletal myofibres and, ideally, within the satellite cell niche. This is a defined anatomical niche along the surface of muscle fibres under the basal lamina that plays an important role in controlling muscle satellite cell selfrenewal and differentiation (reviewed in [108] [109] [110] ). Consequently, this skeletal muscle niche will be equally important for controlling the self-renewal and differentiation of the myogenic ES/iPS cell However, in the case of using iPS cell derivatives to treat inherited disorders, such as muscular dystrophies, the underlying genetic defect would need to be corrected first by ex vivo gene therapy prior to transplantation. iPS cells are also well suited as an in vitro cellular platform for disease modelling and drug screening [115] . Another advantage of using iPS cell-derived cells over adult myogenic stem/progenitor cells is their unlimited proliferation capacity, as in the case of ES cells.
Consequently, the generation of iPS cells requires only a limited number of patient cells, avoiding invasive procedure as in the case of adult stem/progenitor cells. Typically, this has been achieved through the reprogramming of fibroblasts isolated from minimally invasive skin punch biopsies and recent reports have successfully achieved similar results using cells isolated from blood or urine [116, 117] . However, there is evidence that the origin of the cells used to generate iPS cells might bias the differentiation efficiency, in favour of the lineage of the donor somatic cell type (reviewed in [118, 119] ). This likely reflects an 'epigenetic memory' of the cell type of origin that is not fully reset during the reprogramming process. Indeed, this has been shown to be the case for iPS cells derived from mouse myogenic cells versus fibroblasts [120] and human cardiac versus non-cardiac cells [121] .
Though the long-term consequences of this epigenetic memory on pluripotency, safety, cell survival and differentiation are not fully understood, it may facilitate coaxed differentiation of iPS cells into the desired cell type. Nevertheless, robust skeletal myogenic differentiation protocols may potentially override the effects of epigenetic memory on differentiation bias [9] . For ultimate clinical translation it might be worthwhile standardising the tissue of origin of the reprogrammed cell type, to minimize variation in myogenic differentiation efficiencies and safety profiles.
iPS cells have initially been derived by retroviral vector-mediated integration of the reprogramming cassettes. Though very effective, this approach carries an intrinsic risk of insertional oncogenesis [122] . Furthermore, some of the reprogramming factors are de facto oncogenic and their re-expression from the integrated reprogramming cassette cannot be excluded. However, potentially safer alternative reprogramming paradigms have been developed that rely on non-integrating vectors, protein transduction or 'transgene-free' reprogramming during which the reprogramming cassette is episomal or subsequently excised from the iPS genome [123, 124] . Recent studies in non-human primates have laid the foundation for the first-in-man iPS pilot study to assess the safety of using patient-derived iPS cells for the treatment of an eye disorder, age-related macular degeneration [107, [125] [126] [127] . This pilot clinical study is likely to generate critically important information towards extending iPS cell-based clinical protocols to other tissues and diseases.
As with ES cells, the use of iPS cells for the treatment of degenerative muscle disorders requires the establishment of protocols for their efficient directed differentiation into myogenic cells.
Coaxed differentiation of iPS cells into muscle-like cells has mainly been achieved by applying similar
techniques that were initially validated in ES cells. These methods are summarised in Table 2 , and are discussed in more depth below.
Inducing myogenic differentiation of iPS cells using a Pax3 or Pax7 genetic switch
To coax myogenic differentiation of murine or human iPS cells, they have been genetically modified to contain a genetic switch that uses doxycycline-inducible expression of Pax7 during EB differentiation, followed by FACS enrichment for PDGF-R + Flk-1 -cells, or for co-expression of the green fluorescent protein GFP (where GFP is co-transfected/expressed with Pax7) [93, 128] , as described above in ES cells [91, 92] . As with the previous studies, no tumour formation was observed in transplanted mice. Functional improvement as measured by isometric tetanic force, long-term engraftment and restoration of dystrophin expression was noted upon intramuscular transplantation of these cells into cardiotoxin injured dystrophic mice. Our studies were consistent with these findings, and showed that transposon-mediated Pax3 gene transfer in murine iPS cells coaxed their differentiation into multinucleated MyoD + MyHC + myotubes [129] . Similarly, a doxycycline-inducible Pax3 genetic switch was used to derive murine iPS cells from mice who were double knockouts for dystrophin and utrophin [130] . These iPS cell-derived myogenic cells were also able to engraft skeletal muscle of double knockout mice for dystrophin and utrophin upon systemic intravenous (IV) delivery.
However, significant pre-clinical toxicity studies would be necessary to support possible clinical translation of this strategy, as it is not clear what mechanism would prevent the accumulation of IVdelivered cells in filter organs, including the lungs.
Inducing myogenic differentiation of iPS cells using a MyoD switch
MyoD expression is thought to generate a pool of transient-amplifying progenitors at the expense of undifferentiated stem cells; this is a consequence of its role in myogenic commitment. However, it was also reported that a significant number of MyoD-negative satellite cells derive from MyoD-positive parents, supporting the idea that MyoD expression does not necessarily result in terminal differentiation and implying a mechanism to bring cells back to a stem/precursor state even after MyoD expression [61] . Furthermore, we have also reported the generation of donor-derived sublaminar Pax7-positive cells in SCID/mdx muscles transplanted with genetically-corrected mouse mesoangioblasts that also expressed a MyoD transgene [80] . Based upon this evidence and to overcome the limited availability of muscle pericytes in patients with limb-girdle muscular dystrophy 2D (LGMD2D), we developed a protocol to differentiate human iPS cells into pericyte/mesoangioblast-like progenitors that can be expanded in culture (designated as HIDEMs: human iPS-derived mesoangioblast-like cells). To achieve this, a stepwise mesodermal differentiation protocol was employed that does not rely on EB formation and requires no additional FACS purification steps [9, 131] . HIDEMs were genetically corrected (as detailed in the section Ex vivo gene therapy using genetically corrected iPS cells) and then transduced with a lentiviral vector encoding a chimeric, tamoxifen-inducible MyoD-ER(T) (estrogen receptor). Specifically, in the presence of tamoxifen MyoD-ER is translocated to the nucleus where it initiates the myogenic differentiation program. Consequently, myogenic differentiation of the HIDEMs could be accomplished in vitro or in vivo after transplantation into immune-deficient dystrophic mice in a tamoxifen-dependent manner [132] . In support of the safety of this differentiation protocol, we showed that HIDEMs were not tumorigenic in vivo.
An alternative MyoD-based approach was used to differentiate DMD iPS cells [133] . Cells were cultured in myogenic medium to induce mesenchymal differentiation, after which they were transduced with an adenoviral vector expressing MyoD. The iPS cell-derived progenitors were capable of generating multinucleated myotubes in vitro, and upon transplantation into the immunodeficient and dystrophic RAG/mdx mice participated in muscle regeneration. However, potential immunogenicity issues related to the use of adenoviral vectors might limit the application of this strategy.
A MyoD inducible system was also used for myogenic differentiation of human iPS cells from patients with Miyoshi myopathy (MM), an inherited muscular dystrophy caused by dysferlin mutations, and for carnitine palmitoyltransferase II deficiency, an inherited myopathy caused by mutations in CPT2 [134, 135] . This inducible MyoD method differs from those used by us and by Goudenege et al., in that the doxycycline inducible MyoD is transposed directly into the undifferentiated iPS cells. Resulting human MyoD-iPS cells were able to undergo direct myogenic differentiation without a mesodermal transition step (10 days), however the in vivo regenerative potential of the myogenic cells derived using this method remains to be determined. Finally, Abujarour and colleagues also reported direct MyoD-mediated differentiation of iPS cells into myocytes in vitro without the need for an intermediate step or cell sorting [136] . Although relatively faster than other methods, these strategies appear to be more suitable for drug screening than for gene therapy applications. Indeed genetic correction of pluripotent colonies is technically challenging and the absence of an expandable myogenic cell might limit banking and standardization of a possible cellular medicinal product.
Inducing myogenic differentiation of iPS cells without genetic modification
Satellite-like myogenic cells were derived from murine iPS cells using an EB-based protocol followed by FACS enrichment of SM/C-2.6+ cells that was initially developed for ES cells [96, 137] . A similar step-wise EB-based protocol was used to obtain myogenic cells from human ES and iPS cells, which included EB formation followed by dissociation and culture on collagen type-I coated plates with serum containing medium [138] . In this case, there was no enrichment step based on the use of anti-SM/C-2.6 antibodies since they do not bind on human cells. An advantage of these differentiation protocols is that they did not require genetic modification with genes encoding myogenic To identify small molecules capable of promoting myogenesis, Xu and colleagues performed a high-throughput screening to test the ability of 2400 compounds to promote myogenesis in zebrafish embryos [140] . As a result of this screening, the authors identified a 'triple cocktail' of bFGF, the adenylyl cyclase activator forskolin, and the GSK-3 inhibitor BIO that could promote skeletal muscle differentiation when applied to EBs derived from human iPS cells. The resulting cells were also transplanted by intramuscular injection into immunodeficient mice, where they engrafted skeletal muscle. No tumour formation was observed. Although this does not require transgene insertion, the authors did not provide evidence of genetic manipulation/correction of the cells, engraftment in dystrophic muscle or test systemic delivery of these cells.
iPS versus ES derived myogenic stem cells
A head-to-head comparison between human ES and iPS-derived myogenic stem cells [93] [143, 144] . In another study, it was shown that proliferating myogenic progenitors derived from mouse ES (or iPS) cells express major histocompatibility complex (MHC) class I molecules [93] . Elevated MHC class I expression is known to increase their sensitivity towards cytotoxic T cells (CTL) but also suppress natural killer (NK) cellmediated immune response [145] .
Since iPS cells are typically obtained from autologous somatic cells, it was assumed that this would obviate immune concerns after transplantation of its differentiated iPS cell-derived progeny. However, since syngeneic mouse iPS cells have been rejected following transplantation in vivo into mice, this
indicates that even autologous iPS cells can be recognised by the immune system [146] . Hence, the immunogenicity of iPS cells and their derivatives would need to be carefully examined. Nevertheless, analysis of the interaction between human iPS cell-derived mesoangioblasts (HIDEMs) and immune cells suggests a reduced risk of evoking potential immune responses [147] . Indeed, HIDEMs suppress T cell proliferation through IDO and PGE-2 dependent pathways, consistent with the results from tissue-derived mesoangioblasts [148] .
The The use of regulatory T cells (Treg), capable of suppressing or "regulating" the activation of alloreactive lymphocytes [150] represents an alternative strategy that could potentially be exploited to limit alloreactive and/or transgene-specific immune reactions in the context of cell/gene therapy with iPS or ES-derived muscle cells. Interestingly, a particular Treg subtype was enriched in muscle upon acute or chronic injury, and promotes tissue repair in vivo [151] . The possibility to reinforce immune tolerance induction by potentiating Treg activity is an attractive possibility to foster transplant graft acceptance, including that of ES/iPS cell-derived cells [152] . Further studies are needed to investigate the immune consequences of ES/iPS cell-derived myogenic cells in vivo to ensure stable cell engraftment in inflamed muscles.
Ex vivo gene therapy using genetically corrected iPS cells
The development of iPS cell technology in combination with advanced gene therapy methods offers a unique scenario for the treatment of genetic diseases by ex vivo gene therapy, moving closer to the prospect of an autologous and personalized cell therapy. This approach consists of isolating cells from the patient, modifying them in the laboratory, and then transplanting them back into the very same patient, an overview of this potential approach is summarised in Figure 1 
Gene addition
In 2012 we provided the first evidence of successful ex vivo gene therapy using patient-specific differentiated iPS cells for a muscle disorder. Specifically, limb-girdle muscular dystrophy 2D
(LGMD2D) iPS cell-derived inducible myogenic cells (HIDEMs) were genetically corrected with a lentiviral vector encoding the human α-sarcoglycan gene (whose mutations cause LGMD2D) under a muscle specific-promoter and then also transduced with another lentiviral vector encoding a MyoD-ER(T) transgene as a myogenic differentiation switch, as described above. Genetically corrected
LGMD2D HIDEMs were successfully transplanted intramuscularly and intra-arterially into α-sarcoglycan-null immunodeficient (Sgca-null/scid/beige) mice, a preclinical model of LGDM2D, and produced α-sarcoglycan-positive muscle fibres that were detectable one month post transplantation [9] .
Consequently, de novo expression of the missing α -sarcoglycan led to the reconstitution of the dystrophin-associated protein complex in host myofibres. Similarly, species-specific transplantation of mouse iPS cell-derived progenitors in Sgca-null/scid/beige mice led to robust engraftment of large areas of host muscle, re-establishment of muscle pericytes in vivo and functional amelioration of the dystrophic phenotype. This proof of concept study established the validity of an autologous gene therapy approach for the treatment of LGMD2D, and possibly other forms of muscular dystrophy, based upon transplantable iPS cell-derived myogenic cells. Indeed, the same protocol allowed the generation of HIDEMs also from DMD iPS cells, which were genetically corrected with a HAC containing the entire dystrophin genetic locus (DYS-HAC) [9, 153] . This stably maintained, episomal DYS-HAC accommodates the entire genomic dystrophin locus (2.4 Mb) avoiding integrationassociated risks. Furthermore, such delivery of the entire gene is mutation independent, thus ensuring applicability to the variety of mutations/duplications/deletions that cause DMD.
A different approach for the treatment of DMD has been proposed by Filareto et al., where the dystrophic phenotype of dystrophin/utrophin null mouse iPS cells was corrected by providing microutrophin (µUTRN) with a non viral vector Sleeping Beauty transposon [130] . Utrophin is a protein closely related to dystrophin, whose over expression has been shown to ameliorate the dystrophic phenotype in mdx mice [154] . In order to achieve myogenic differentiation Filareto et al. importantly, this strategy is so far limited to mouse iPS cells and data supporting its validity using DMD iPS cells will be necessary in order to consider potential clinical translation.
By using a similar gene transfer approach, in the work of Tanaka Furthermore, extensive analysis must be conducted to delineate the integration profile of transposons in iPS cells in order to exclude the risk of insertional mutagenesis and move towards clinical applications.
Targeted gene editing
The use of designer nucleases such as ZFNs, TALENs and CRISPR/Cas9 allows for efficient targeted gene correction of the dystrophin locus in iPS cells and/or myogenic progenitor cells and therefore provides an attractive alternative to the aforementioned gene addition strategies. These powerful genome engineering tools have shown great effectiveness for the correction of disease mutations in iPS cells for several diseases such as ß-thalassemia [155] , α1-antitrypsin deficiency [156] and epidermolysis bullosa [157] . In a recent work, neural stem cells (NSCs) generated from iPS cells of myotonic dystrophy type 1 (DM1) patients were corrected in vitro by TALEN-mediated homologous recombination (HR) [158] . These results provide the first proof-of-principle evidence that TALENs may be used to generate genetically modified DM1 progenitor cells as a first step toward autologous cell transfer therapy for DM1. An extension of this approach to revert a possible muscle phenotype of DM1 iPS cell-derived myogenic progenitors might be considered as a promising area of investigation.
In the case of DMD, proof-of-concept had been established by Gersbach and colleagues, who demonstrated correction of the dystrophin open reading frame using TALENs specifically design to target and edit the dystrophin exon 51 locus [159] . This led to restoration of dystrophin protein expression in DMD skeletal myoblasts and dermal fibroblasts that were reprogrammed to the myogenic lineage by forced expression of MyoD. There was no evidence of off-target effects based on exome sequencing of in silico predicted target sites, suggesting that TALEN-mediated genome editing was highly specific for the target locus. An alternative approach was based on ZFNs that were specifically designed to permanently remove essential splicing sequences in exon 51 of the dystrophin gene and thereby exclude exon 51 from the resulting dystrophin transcript [160] . DMD myoblasts engineered using these designer ZFNs contained the expected deletion of exon 51 resulting in concomitant restoration of dystrophin protein expression. Furthermore, transplantation of the ZFN-corrected myoblasts into immunodeficient mice resulted in human dystrophin expression in vivo. This provides an attractive alternative to oligonucleotide-induced exon skipping to permanently and irreversibly restore the dystrophin reading frame and protein production, obviating the need for continuous drug administration. One caveat of these proof-of-concept studies is that they are based on DMD myoblasts, which are not ideally suited for cell therapy in DMD patients based on their limited proliferation potential and inability to efficiently migrate out of the blood stream following their systemic intravascular administration.
In a recent study, a multiplex CRISPR/Cas9-based gene editing system has been designed to restore the dystrophin reading frame in DMD myoblasts by targeting the mutational hotspot at exons 45-55 [161] . Although this approach has the advantage to correct potentially more than 60% of DMD patient mutations with a single genome-editing strategy, the final product is a shorter version of the human dystrophin. In another study, instead, the specificity of the TALEN/CRISPR gene editing system for mutations/deletions in the dystrophin gene that lead to a lack of exon 44 has been explored to restore the expression of the full-length human dystrophin in DMD patient-derived iPS cells [162] .
The high specificity of the nuclease design was done after a comprehensive genome-wide mutation analyses to assess the risk of off-target mutagenesis in DMD iPS cell clones treated according to the 
TRANSLATIONAL CHALLENGES AND CONCLUDING REMARKS
The clinical translation of iPS cells for the autologous gene and cell therapy of genetic diseases represents perhaps one of the greatest challenges of modern molecular medicine. Even though this process may benefit from the knowledge acquired to translate viral vectors into new therapeutics [163, 164] , several hurdles are being (or will need to be) addressed to successfully complete this process, including: possible genome instability, residual undifferentiated tumorigenic cells, large scale production under GMP/GLP grade regulations, preservation of self-renewing potential, epigenetic memory of the cells of origin and re-expression of potentially oncogenic reprogramming factors (e.g. Myc). In the case of skeletal muscle and its diseases, this also needs to be considered in the context of other tissue-specific obstacles, including the need to target the diaphragm and the heart in order to counteract the cardiac and respiratory failure that underline several forms of muscular dystrophy (e.g.
DMD).
Pluripotent stem cells offer the invaluable prospect of obtaining an unlimited number of cells for regenerative therapies, which is vital for the treatment of muscular dystrophies (skeletal muscle being the most abundant human tissue). Indeed recent clinical studies highlight the need to use large number of cells to treat dystrophic patients, the amount of cells and their delivery depending primarily on the type of cells and disorder. Local transplantation of autologous myoblasts in the pharyngeal muscles of OPMD patients showed that improvements in both swallowing and quality of life were observed in patients who had been injected with more than 178 million cells [67] . On the other hand, to test the safety of allogeneic transplantation of mesoangioblasts in DMD children the average amount of transplanted cells was in the order of 10 9 per patient. Then, to reach clinical efficacy, it is expected that a dose of cells significantly higher than this would be required. Transplanted cell engraftment and contribution to host myofibres are key issues to face in cell therapy. Satellite cell long-lasting selfrenewal has been showed for up to 7 rounds of transplantation with as little as 16 cells [58] . These findings support the idea that for a successful cell therapy, the self-renewal potential of the donor cells might be as important as their capability to be expanded extensively.
Further studies are needed to optimise genome-integration-and animal-component-free protocols that can be used for the large-scale production of iPS cells, and for the derivation/purification of myogenic cells from iPS cells under GMP/GLP conditions. Moreover, new chemically-defined methods should also focus on obtaining myogenic progenitors able to migrate and engraft into muscles upon loco-regional/systemic delivery, thus improving the likelihood of efficacy of such therapies.
Different vectors have been exploited for the ex vivo correction of patient/disease-specific iPS cells. Theoretically the most valuable of the studied gene therapy approaches are those able to provide functional expression of the missing gene irrespective of the underlying mutation, and will thus be applicable to a larger number of patients. However, the recent introduction of fast and cost-effective CRISPR/Cas9-based gene editing platform might also shift this paradigm toward a more "a la carte" personalised approach. Furthermore, for safe ex vivo genetic correction the risk of vector-induced immune responses needs to be thoroughly investigated, and the danger of insertional mutagenesis avoided either through the use of site-specific integration or non-integrating systems that are stably maintained.
In conclusion, emerging methods for the generation and genetic correction of pluripotent stem cells and their myogenic derivatives have an extraordinary potential for the cell therapy of muscle disorders, and many encouraging initial results have been described in this review. We believe that the recent effort to translate iPS cells into medicinal products for cell therapies [125] [126] [127] may provide invaluable insights for the future challenge of autologous iPS cell-based therapies for muscle diseases. 
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